Large-scale and high-resolution mass spectrometry-based proteomics profiling defines molecular subtypes of esophageal cancer for therapeutic targeting - Liu, Wei; Xie, Lei; He, Yao-Hui; Wu, Zhi-Yong; Liu, Lu-Xin; Bai, Xue-Feng; Deng, Dan-Xia; Xu, Xiu-E; Liao, Lian-Di; Lin, Wan; Heng, Jing-Hua; Xu, Xin; et al. (Nature communications, 2021)
Keywords: 13/1; 13/51; 631/337/475; 631/67/1059/153; 631/67/1857; 64/60; 82/58; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cancer; Cell Cycle; Cohort Studies; Drug development; Drugs; Elongin - genetics; Elongin - metabolism; Esophageal cancer; Esophageal Neoplasms - genetics; Esophageal Neoplasms - metabolism; Esophagus; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humanities and Social Sciences; Humans; Mass spectrometry; Mass Spectrometry - methods; Mass spectroscopy; multidisciplinary; Patients; Prognosis; Proteins; Proteomics; Ribosomal proteins; Science; Science (multidisciplinary); Scientific imaging; Serine-Arginine Splicing Factors - genetics; Serine-Arginine Splicing Factors - metabolism; Spectroscopy; Therapeutic targets; Tumors